Therapy with SR18662 significantly cuts down progress and proliferation of CRC cells. SR18662 shows enhanced efficacy in decreasing viability of several CRC mobile lines. Stream cytometry analysis pursuing SR18662 therapy demonstrates an increase in cells captured in either S or G2/M phases on the mobile cycle and a substantial increase in the quan